What Factors Contribute to Hologic's GYN Surgical Success Amidst Market Competition?

Hologic's Position in the Global Women's Health Devices Market

According to a recent report from Global Market Insights, Hologic (HOLX) is projected to hold over 18% of the worldwide women’s health devices market by 2025. The sector is expected to grow at a compound annual growth rate of 10.2% between 2026 and 2035, fueled by increasing rates of gynecological and chronic diseases among women, heightened awareness of preventive healthcare, and a rising preference for minimally invasive diagnostic and treatment options. Hologic’s GYN Surgical division, one of its primary business segments, has consistently performed well in recent quarters.

The company has achieved growth through both in-house innovation and strategic acquisitions, capitalizing on its robust sales infrastructure. In the first quarter of fiscal 2026, surgical revenue reached $180.8 million, reflecting a 7.5% year-over-year increase at constant currency. This growth was primarily driven by strong sales of MyoSure and Fluent devices, as well as the integration of the Gynesonics acquisition.

Internationally, Hologic has broadened its presence by investing in commercial operations and market access, significantly extending the reach of its minimally invasive surgical offerings. MyoSure has seen greater adoption outside the U.S., signaling substantial opportunities in global markets where demand for less invasive treatments for uterine polyps and fibroids remains high. The acquisition of the Acessa laparoscopic fibroid removal system in 2021 further complemented MyoSure by enabling treatment of larger or more complex fibroids.

NovaSure has maintained robust double-digit growth in overseas markets in recent quarters. In fiscal 2025, Hologic also added the Sonata system through its purchase of Gynesonics, giving surgeons new options for treating symptomatic uterine fibroids, including those responsible for heavy menstrual bleeding.

Comparing Hologic with Medtronic and Johnson & Johnson

In the GYN Surgical space, Hologic faces competition from major players such as Medtronic (MDT) and Johnson & Johnson (JNJ), both of which offer comprehensive surgical solutions. In February 2026, Medtronic announced the first U.S. commercial procedure using its FDA-cleared Hugo robotic-assisted surgery system, with plans to expand its use from urology into gynecologic and general surgeries, including hernia repair.

Johnson & Johnson’s MedTech division features a broad portfolio of surgical products and enabling technologies for open, laparoscopic, and robotic procedures. Recently, the company introduced the CEREGLIDE 42 and CEREGLIDE 57 aspiration catheters and the INNERGLIDE 7 delivery aid in the U.S., expanding its aspiration-first stroke treatment lineup.

Hologic's Stock Trends, Valuation, and Analyst Estimates

Over the past year, Hologic’s stock price has climbed 20.7%, outperforming an industry decline of 3.8%.

Image Source: Zacks Investment Research

The company currently trades at a forward 12-month price-to-sales ratio of 3.88, which is higher than its median but below the industry average. Hologic presently holds a Value Score of C.

Image Source: Zacks Investment Research

Below is a look at the latest trends in Hologic’s earnings estimates:

Image Source: Zacks Investment Research

Currently, Hologic is rated as a Zacks Rank #4 (Sell).